AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...